PMID- 25947394
OWN - NLM
STAT- MEDLINE
DCOM- 20160329
LR  - 20181113
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 128
IP  - 9
DP  - 2015 May 5
TI  - Effect of Intravenous Administration of Liposomal Prostaglandin E1 on 
      Microcirculation in Patients with ST Elevation Myocardial Infarction Undergoing 
      Primary Percutaneous Intervention.
PG  - 1147-50
LID - 10.4103/0366-6999.156078 [doi]
AB  - BACKGROUND: Several studies have demonstrated that primary percutaneous coronary 
      intervention (PCI) can result in reperfusion injury. This study aims to 
      investigate the effectiveness of liposomal prostaglandin E1 (Lipo-PGE1, 
      Alprostadil, Beijing Tide Pharmaceutical Co., Ltd.) for enhancing 
      microcirculation in reperfusion injury. In addition, this study determined the 
      optimal administration method for acute ST elevation myocardial infarction 
      (STEMI) patients undergoing primary PCI. METHODS: Totally, 68 patients with STEMI 
      were randomly assigned to two groups: intravenous administration of Lipo-PGE1 
      (Group A), and no Lipo-PGE1 administration (Group B). The corrected thrombolysis 
      in myocardial infarction (TIMI) frame count (cTFC) and myocardial blush grade 
      (MBG) were calculated. Patients were followed up for 6 months. Major adverse 
      cardiac events (MACE) were also measured. RESULTS: There was no significant 
      difference in the baseline characteristics between the two groups. The cTFC 
      parameter in Group A was significantly lower than Group B (18.06 +/- 2.06 vs. 25.31 
      +/- 2.59, P < 0.01). The ratio of final MBG grade-3 was significantly higher (P < 
      0.05) in Group A (87.9%) relative to Group B (65.7%). There was no significant 
      difference between the two groups in final TIMI-3 flow and no-reflow. Patients 
      were followed up for 6 months, and the occurrence of MACE in Group A was 
      significantly lower than that in Group B (6.1% vs. 25.9% respectively, P < 0.05). 
      CONCLUSIONS: Myocardial microcirculation of reperfusion injury in patients with 
      STEMI, after primary PCI, can be improved by administering Lipo-PGE1.
FAU - Wei, Li-Ye
AU  - Wei LY
FAU - Fu, Xiang-Hua
AU  - Fu XH
AD  - Department of Cardiology, The Second Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050000, China.
FAU - Li, Wei
AU  - Li W
FAU - Bi, Xi-Le
AU  - Bi XL
FAU - Bai, Shi-Ru
AU  - Bai SR
FAU - Xing, Kun
AU  - Xing K
FAU - Wang, Yan-Bo
AU  - Wang YB
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - F5TD010360 (Alprostadil)
SB  - IM
MH  - Administration, Intravenous
MH  - Aged
MH  - Alprostadil/*administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Microcirculation/drug effects
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Percutaneous Coronary Intervention/*methods
PMC - PMC4831538
COIS- Conflict of Interest: None declared.
EDAT- 2015/05/08 06:00
MHDA- 2016/03/30 06:00
PMCR- 2015/05/05
CRDT- 2015/05/08 06:00
PHST- 2015/05/08 06:00 [entrez]
PHST- 2015/05/08 06:00 [pubmed]
PHST- 2016/03/30 06:00 [medline]
PHST- 2015/05/05 00:00 [pmc-release]
AID - ChinMedJ_2015_128_9_1147_156078 [pii]
AID - CMJ-128-1147 [pii]
AID - 10.4103/0366-6999.156078 [doi]
PST - ppublish
SO  - Chin Med J (Engl). 2015 May 5;128(9):1147-50. doi: 10.4103/0366-6999.156078.